Omeros Corporation OMER
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2009-10-08 |
| Shares Out. | 72,390,000 |
| Website | omeros.com/ ↗ |
| Phone | 12066765000 |
| Employees | 175 |
| Revenue | $28.5M |
| Gross Profit | $27.7M |
| Net Income | $13.2M |
| Free Cash Flow | -$68.7M |
| Total Assets | $286.8M |
| Total Liabilities | $338.2M |
| Equity | -$51.3M |
About Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Omeros Corporation is a publicly traded company under the ticker symbol OMER on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-11-01)